In connection with the Transaction, on October 3, 2023, the Histogen Inc. and Allergan mutually elected to terminate the Amended and Restated License Agreement by and between the Company and Allergan (as assigned to Allergan by Suneva Medical Inc. (?Suneva?), dated December 16, 2013, as amended from time to time and the Amended and Restated Supply Agreement by and between the Company and Allergan (as assigned to Allergan by Suneva), dated December 16, 2013, as amended from time to time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 USD | 0.00% | +25.00% | -35.00% |
19/04 | Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc. | CI |
18/04 | Histogen Inc. Filed for Bankruptcy | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.00% | 9L | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.23TCr | |
-3.70% | 2.19TCr | |
-6.03% | 1.86TCr | |
-35.21% | 1.81TCr | |
-10.86% | 1.7TCr | |
+5.10% | 1.37TCr | |
+37.57% | 1.24TCr |
- Stock Market
- Equities
- HSTO Stock
- News Histogen Inc.
- Histogen Inc. and Allergan Mutually Elect to Terminate the Amended and Restated License Agreement